Akebia Therapeutics (AKBA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.09 per share a year ago.

Akebia Therapeutics AKBA shares increased by 12.6% to $2.77. The company's market cap stands at $723.6 million. As per the press release, Q1 earnings came out today. Losers ...

Akebia Therapeutics (AKBA) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook ...

NASDAQ:AKBA opened at $2.38 on Friday. Akebia Therapeutics has a 52 week low of $0.80 and a 52 week high of $2.89. The stock’s fifty day moving average is $1.95 and its two-hundred day moving ...

Jefferies Financial Group assumed coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) in a research note issued to investors on Tuesday, Marketbeat reports. The firm issued a ...

In this article, we are going to take a look at where Akebia Therapeutics Inc. (NASDAQ:AKBA) stands against other Thursday’s worst-performing stocks. Wall Street’s main indices edged lower on ...

In this article, we are going to take a look at where Akebia Therapeutics, Inc. (NASDAQ:AKBA) stands against other stocks to invest in for a stock market game. We all have heard the phrase ...

AKBA stock touches 52-week high at $2.48 amid robust gains View all comments (0) 0 Latest comments Post Comment Guidelines Trade With A Regulated Broker Indices Commodities Bonds Stocks US 30 ...